DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom Real-Time API, which enables invited third-party developers to integrate real-time CGM data into their digital health applications and devices; Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions; and Dexcom Share, a remote monitoring system. The company's products candidature comprises Dexcom G7, a next generation G7 CGM system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was incorporated in 1999 and is headquartered in San Diego, California.

DexCom, Inc.

CopilotIQ focuses on remote health monitoring for seniors, particularly in managing chronic conditions like diabetes and hypertension through a telehealth platform that provides personalized care and monitoring by US-based licensed nurses.

CopilotIQ

QuidelOrtho provides diagnostic solutions and products aimed at enhancing healthcare through testing capabilities in both at-home and clinical settings. Self-described as offering solutions across the healthcare continuum.

QuidelOrtho

Circadia Health offers a contactless remote monitoring platform for long term care facilities, designed to detect biosignals and improve patient outcomes.

Circadia Health

Dexcom develops and manufactures continuous glucose monitoring (CGM) systems for diabetes management.

Dexcom

Dexcom Corporation is a pioneer and global leader in continuous glucose monitoring (CGM).  Dexcom began as a small company with a big dream: To forever change how diabetes is managed. To unlock information and insights that drive better health outcomes. Here we are 25 years later, having pioneered an industry. And we're just getting started.  We are broadening our vision beyond diabetes to empower people to take control of health. That means personalized, actionable insights aimed at solving important health challenges. To continue what we've started: Improving human health. We are driven by over 10,000 ambitious, passionate people worldwide who are willing to fight like warriors to earn the trust of our customers by listening, serving with integrity, thinking big, and being dependable. We've already changed millions of lives and we're ready to change millions more.  Our future ambition is to become a leading consumer health technology company while continuing to develop solutions for serious health conditions. We'll get there by constantly reinventing unique biosensing-technology experiences. Though we've come a long way from our small company days, our dreams are bigger than ever. The opportunity to improve health on a global scale stands before us.

Metric
Company Name	DexCom, Inc.	CopilotIQ	QuidelOrtho	Circadia Health
Symbol	DXCM
MSH ID	COM:DEXCOM	COM:COPILOTIQ	COM:QUIDEL	HEALTH:CIRCADIA
Market	STOCKS	PRIVATE	PRIVATE	PRIVATE
Sector	Healthcare	Healthcare & Health Services	Healthcare & Health Services	Healthcare & Health Services
Industry	Medical - Devices	Healthcare Technology	Medical Devices and Diagnostics	Health Technology
Country	US	US	US	US
Stage
Employee Count	9.50K	101
Website	dexcom.com	copilotiq.com	quidel.com	circadia.health
LinkedIn	dexcom
Founders

Metric
Market Cap	44.06B
Enterprise Value
Monthly Web Traffic	4.27M	33.24K
Web Traffic Growth	1.06	-0.12
Valuation
Raised Capital	1B

Metric
Revenue	3.62B
Revenue (LTM)
Revenue (NTM)
Gross Profit	2.29B
EBITDA	916.70M
Operating Income	597.70M
Net Income	541.50M
EPS	1.40
Diluted EPS	1.30
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	0.63
Operating Profit Margin	0.17
EBITDA Margin	0.25
Net Profit Margin	0.17
Return on Equity	0.30
Return on Assets	0.10
Return on Capital Employed	0.13

COM:DEXCOM

Dexcom

Last Close

74.46

22/11 21:00

Market Cap

44.06B

Beta: -

Volume Today

4.45M

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	124.03
P/B Ratio	20.62
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	14.04
EV Multiple	61.92

Metric
Days Sales Outstanding	84.27
Days Payables Outstanding	407.66
Days Inventory Outstanding	153.18
Operating Cycle	252.69
Cash Conversion Cycle	177.03
Asset Turnover	0.59

Metric
Operating Cash Flow	748.50M
Free Cash Flow	511.90M
Cash Flow to Debt	0.36
Operating Cash Flow/Sales	0.23
Free Cash Flow Yield	0.01

Metric
Cash & Equivalents	566.30M
Accounts Receivable	-260.10M
Inventory	559.60M
Goodwill	25.20M
Debt to Capitalization	0.56
Debt to Assets	0.40
Current Ratio	2.80
Quick Ratio	2.53

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue	0.04
R&D to Revenue	0.14
SG&A to Revenue